2 days ago
@yahoofinaceBefore the agreement with Mesoblast, Grünenthal redefined the realignment of the research and development organization. Cell and gene therapy is laid down as a core competence. The entire research and development department has been heavily restructured, which also involves layoffs. If I interpret this correctly, there is no doubt about the success of cell therapy at Grünenthal - neither do we as Meso shareholders!
https://www.grunenthal.com/en/press-room/view-press-release?pressReleaseId=3098e512-9967-4186-a2dc-26122cfa6b6e
Seanpierre12 days ago@yahoofinaceBefore the agreement with...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
-0.095(8.76%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.12 | 98.0¢ | $26.84M | 25.91M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 25272 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 6571 | 1 |
View Market Depth
| Last trade - 16.10pm 30/04/2024 (20 minute delay) ? |
|
|||||
|
Last
99.5¢ |
Change
-0.095 ( 7.78 %) |
||||
| Open | High | Low | Volume | ||
| $1.12 | $1.12 | 98.0¢ | 3288218 | ||
| Last updated 15.59pm 30/04/2024 ? | |||||
| MSB (ASX) Chart |